|
|
|
| Effect of Cinobufacini tablets, Erbitux Injection Combined with Chemotherapy on Patients with Advanced Non-small Cell Lung Cancer |
| XIAO Qi, WANG Xiao-jie, XIE Ming-shui, et al |
| Department of Oncology, the 92 Hospital of PLA, Fujian, Nanping 353000 |
|
|
|
|
Abstract 【Objective】To investigate the clinical efficacy and quality of life of patients with advanced non small cell lung cancer (NSCLC) treated with Cinobufacini tablets and Erbitux injection combined TP chemotherapy.【Methods】Seventy-three cases of patients with advanced NSCLC were divided into the observation group (group A) and the control group (group B) . The group B was treated with TP (paclitaxel and cisplatin) chemotherapy, and the group A was treated with cinobufacini tablets and Erbitux injection on the basis of treatment in the group B. The short-term efficacy, adverse reactions, and related changes before and after treatment were compared between the two groups.【Results】The total effective rate of the observation group was 59.46% (22/37) , which was significantly higher than 33.33% (12/36) of the control group (P<0.05) , but there was no significant difference in the disease control rate between the two groups (P>0.05) ; the levels of serum interleukin -6 (IL-6) , IL-10, CA125, carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF) in the observation group were significantly lower than those in the observation group after treatment; IL-17, TNF-αlevel was significantly higher than that of the control group, and the difference was significant (P<0.05) ; the improvement rate of survival quality in the observation group was 48.65% (18/37) , which was significantly higher than 25% (9/36) in the control group (P < 0.05) ; the incidence of nausea and vomiting, white blood cell reduction and anemia in the observation group were lower than those in the control group (P<0.05) .【Conclusion】Cinobufacini tablets, Erbitux injection combined with TP chemotherapy can effectively improve the short-term efficacy, regulate immune abnormalities, enhance immune function, and significantly improve the quality of life in patients with advanced NSCLC.
|
|
Received: 07 August 2017
|
|
|
|
|
|
[1] 余浪. 恩度联合顺铂治疗非小细胞肺癌恶性胸腔积液的疗效观察[J]. 医学临床研究, 2016, 33(6):1135-1137.
[2] 卢宏丽, 卢宏霞. 华蟾素联合化疗治疗中晚期非小细胞肺癌的临床疗效[J]. 中国药物与临床, 2015, 15(11):1609-1610.
[3] Chen G, Kronenberger P, Teugels E, et al. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab[J]. BMC Med, 2012, 10( 1) : 28.
[4] 范正菊. 西妥昔单抗联合多西紫杉醇对晚期非小细胞肺癌患者生存时间的影响分析[J]. 临床肺科杂志, 2015, 20(7):1202-1204, 1205.
[5] 王婉茹, 洪滨, 李康等. 华蟾素注射液辅助治疗晚期NSCLC的疗效评估[J]. 临床肺科杂志, 2013, 18(2):203-204.
[6] 刘宝东. 华蟾素联合化疗治疗非小细胞肺癌的临床疗效观察[J]. 临床和实验医学杂志, 2014, 13(15):1263-1265.
[7] 胡章华. 华蟾素注射液联合TP方案治疗晚期非小细胞肺癌的临床观察[J]. 中国药房, 2012, 23(16):1507-1510.
[8] Wilke C M, Kryczek I, Wei S, et al. Th17 cells in cancer: help or hindrance[J]. Carcinogenesis, 2011, 32(5) : 643-649. |
|
|
|
2017, Vol. 34 
